These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33113616)

  • 1. [Current treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia in the TKI era].
    Shen YJ; Zhu HH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):779-782. PubMed ID: 33113616
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Zeng Q; Xiang B; Liu Z
    Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
    Dobashi N
    Rinsho Ketsueki; 2020; 61(9):1227-1235. PubMed ID: 33162520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Hematology Am Soc Hematol Educ Program; 2011; 2011():231-7. PubMed ID: 22160039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
    Ma Y; Zhang Q; Kong P; Xiong J; Zhang X; Zhang C
    Chemotherapy; 2019; 64(2):81-93. PubMed ID: 31390613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
    Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia.
    Halahleh K; Al Rimawi D; Abu Ghosh A; Muradi I; Da'na W; Hamadani M
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):219-222. PubMed ID: 34352199
    [No Abstract]   [Full Text] [Related]  

  • 9. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
    Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nakasone H
    Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang Y; Feng S
    Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
    Shimada H
    Rinsho Ketsueki; 2022; 63(7):799-804. PubMed ID: 35922951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Thomas X; Dombret H
    Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance.
    Ottmann O
    Lancet Haematol; 2018 Dec; 5(12):e606-e607. PubMed ID: 30501865
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Onizuka M
    Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
    Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.